Mylan gets Fed Circ reprieve in inhaler dispute

In a win for Mylan Pharmaceuticals, a US Court of Appeals for the Federal Circuit panel has ruled it can revisit a decision that held the generic maker infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.

More on this story

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.

More on this story

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.